Sugi Predict

Sugi Predict / Compounds / SCHEMBL120550

SCHEMBL120550

SCHEMBL120550

Nc1ncnc2c1ncn2[C@]1(C2CCCC2)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 5/20 0.51
▸ ADORA2A P29274 3/20 0.51
▸ SLC28A1 O00337 2/20 0.51
▸ PI4KA P42356 2/20 0.51
▸ PI4K2B Q8TCG2 2/20 0.51
▸ PI4K2A Q9BTU6 2/20 0.51
▸ PI4KB Q9UBF8 2/20 0.51
▸ DPP4 P27487 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ MAP3K7 O43318 1/20 0.51
▸ SLC28A2 O43868 1/20 0.51
▸ GAPDH P04406 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ADORA2B P29275 1/20 0.51
▸ ADORA1 P30542 1/20 0.51
▸ STAT6 P42226 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ DOT1L Q8TEK3 1/20 0.51
▸ SLC29A1 Q99808 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120561 0.99 ADORA3 (0.50) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL10689174 0.96 ADORA3 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL8608777 0.93 ADORA3 (0.50) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL8608416 0.91 ADORA3 (0.47) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL10604311 0.91 ADORA3 (0.45) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL10870435 0.90 EHMT1 (0.45) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL8608410 0.89 SLC28A1 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL8606010 0.87 SLC28A1 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL28822391 0.86 ADORA3 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL11006064 0.86 ADORA3 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024243-A1 Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same LABORATORY SKIN CARE, INC. 2024-01-25 — — US claimed
US-20190125779-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2019-05-02 — — US claimed
WO-2018091689-A1 SKELETAL MUSCLE HYPERTROPHY INDUCERS CYTOO (FR) 2018-05-24 — — WO claimed
EP-3247715-A1 METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION Inotek Pharmaceuticals Corporation (US) 2017-11-29 — — EP claimed
WO-2017137528-A1 ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2017-08-17 — — WO claimed
US-20160367586-A1 COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE INOTEK PHARMACEUTICALS CORPORATION 2016-12-22 — — US claimed
WO-2016109624-A1 PHARMACEUTICAL COMPOSITIONS UNIVERSITY OF HOUSTON SYSTEM (US) 2016-07-07 — — WO claimed
US-20160158268-A1 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS INOTEK PHARMACEUTICALS CORPORATION 2016-06-09 — — US claimed
US-20160158267-A1 METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION INOTEK PHARMACEUTICALS CORPORATION 2016-06-09 — — US claimed
WO-2016090005-A1 METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION INOTEK PHARMACEUTICALS CORPORATION (US) 2016-06-09 — — WO claimed
WO-1998019674-A2 A METHOD FOR TREATING TENSION-TYPE HEADACHE HEAD EXPLORER APS (DK) 1998-05-14 — — WO claimed
WO-1998015276-A1 COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION THERASYS, INC. (US) 1998-04-16 — — WO claimed
EP-0735888-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA, Atsuo F. (US) 1996-10-09 — — EP claimed
WO-1995014478-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA ATSUO F (US) 1995-06-01 — — WO claimed
EP-0589964-A4 METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY UNIV VANDERBILT (US) 1994-05-25 — — EP claimed
EP-0589964-A1 METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY VANDERBILT UNIVERSITY (US) 1994-04-06 — — EP claimed
WO-1992020346-A1 METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY VANDERBILT UNIVERSITY (US) 1992-11-26 — — WO claimed
US-5070877-A Using adenosin receptor agonist MEDCO RESEARCH, INC. (US) 1991-12-10 — — US claimed
EP-0181129-B1 N6-SUBSTITUTED DEOXYRIBOSE ANALOGS OF ADENOSINES WARNER-LAMBERT COMPANY (US) 1989-03-08 — — EP claimed
EP-0181129-A2 N6-substituted deoxyribose analogs of adenosines WARNER-LAMBERT COMPANY (US) 1986-05-14 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158267-A1 METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION ADORA2A, ADORA1, PDE6C ADORA3 4/4885ADORA2A 1/4885SLC28A1 411/4885
US-20160367586-A1 COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE PTGIR, ADORA1, PDE3A ADORA3 7/4885ADORA2A 4/4885SLC28A1 201/4885
US-20160158268-A1 METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS PDE3A, PDE2A, PDE6C ADORA3 31/4885ADORA2A 25/4885SLC28A1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.